cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid | 708-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid
• 英文别名: cis-1-Methyl-indan-2-carbonsaeure；cis-1-Methylindan-2-carbonsaeure；(1S,2S)-1-methyl-2,3-dihydro-1H-indene-2-carboxylic acid
• CAS: 708-37-2；16440-72-5；25871-13-0；28278-37-7；28278-38-8
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: IHSLASJHLBMFJC-XCBNKYQSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid 在 氯化亚砜 作用下， 生成 cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid chloride
  参考文献：
  名称：

  4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and

  摘要：

  一种制备式##STR1##的取代咪唑的方法，其中X为--CH.sub.2 --，--CH.sub.2 CH.sub.2 --或--O--，R.sub.1为H，低烷基或低烯基，OCH.sub.3或OCH.sub.2 CH.sub.3，R.sub.2为H，CH.sub.3，CH.sub.2 CH.sub.3，OCH.sub.3或OH，R.sub.3为H，CH.sub.3，CH.sub.2 CH.sub.3，OCH.sub.3或Hal，R.sub.4为H，CH.sub.3，CH.sub.2 CH.sub.3，OCH.sub.3或Hal，Hal为卤素，它们的无毒酸盐具有有价值的药理活性，特别适用于作为选择性α2-受体拮抗剂。

  公开号：

  US04689339A1

文献信息

• Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof
  申请人：Duan Jingwu

  公开号：US20070185056A1

  公开（公告）日：2007-08-09

  Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A 1 QA 2 -; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR 5 —, —SO p —, —SO p NR 5 —, —C(O)O—, —NR 5 C(O)—, —OC(O)NR 5 —, —NR 5 C(O)O—, —S(O) p NR 5 C(O)—, —C(O)NR 5 S(O) p — —NR 5 S(O) p —, or —NR 5 C(═O)NR 6 —. Y is selected from hydrogen, C 1-4 alkyl, OR 16 , substituted C 1-6 alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A 1 and A 2 are independently selected from a bond, C 1-3 alkylene, or C 1-3 alkenylene, and R 1 -R 11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

  提供了一种新型的非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症性和免疫性疾病，其具有以下结构的化学式（I）： 或其对映体、非对映体、药用可接受的盐或水合物，其中X为-A 1 QA 2 -；Q为键，—C(═O)—，—OC(O)—，—C(═O)NR 5 —，—SO p —，—SO p NR 5 —，—C(O)O—，—NR 5 C(O)—，—OC(O)NR 5 —，—NR 5 C(O)O—，—S(O) p NR 5 C(O)—，—C(O)NR 5 S(O) p —，—NR 5 S(O) p —，或—NR 5 C(═O)NR 6 —。Y从氢、C 1-4 烷基、OR 16 、取代的C 1-6 烷基、环烷基、芳基、杂环烷基和杂芳基中选择。A 1 和A 2 独立选择自键、C 1-3 烷基或C 1-3 烯基，R 1 -R 11 在此定义。还提供了包含所述化合物的药物组合物、组合物和治疗肥胖、糖尿病和炎症性或免疫相关疾病的方法。
• INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Duan Jingwu

  公开号：US20090325961A1

  公开（公告）日：2009-12-31

  Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A 1 QA 2 -; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR 5 —, —SO p —, —SO p NR 5 —, —C(O)O—, —NR 5 C(O)—, —OC(O)NR 5 —, —NR 5 C(O)O—, —S(O) p NR 5 C(O)—, —C(O)NR 5 S(O) p — —NR 5 S(O) p —, or —NR 5 C(═O)NR 6 —. Y is selected from hydrogen, C 1-6 alkyl, OR 16 , substituted C 1-6 alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A 1 and A 2 are independently selected from a bond, C 1-3 alkylene, or C 1-3 alkenylene, and R 1 -R 11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

  本发明提供了一些新型非类固醇化合物，其可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节有关的疾病，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构式为(I)：或其对映异构体、顺异构体或药学上可接受的盐或水合物，其中X为A1QA2-；Q为键，—C（═O）—，—OC（O）—，—C（═O）NR5—，—SOp—，—SOpNR5—，—C（O）O—，—NR5C（O）—，—OC（O）NR5—，—NR5C（O）O—，—S（O）pNR5C（O）—，—C（O）NR5S（O）p—，—NR5S（O）p—或—NR5C（═O）NR6—。Y选自氢、C1-6烷基、OR16、取代的C1-6烷基、环烷基、芳基、杂环烷基和杂环芳基。A1和A2独立地选自键、C1-3烷基或C1-3烯基，R1-R11在此定义。还提供了包含上述化合物的药物组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。
• Substituted imidazole derivatives and their preparation and use
  申请人：Farmos-Yhtyma Oy

  公开号：EP0183492A1

  公开（公告）日：1986-06-04

  The compounds of the formula: wherein X is -CH2-, -CH2CH2- or -0-, R1 is H, lower alkyl or lower alkenyl group, OCH3 or OCH2CH3, R2 is H, CH3, CH2CH3, OCH3 or OH, R3 is H, CH3, CH2CH3, OCH3 or Hal, R4 is H, CH3, CH2CH3, OCH3 or Hal, and Hal is halogen, and their non-toxic acid addition salts exhibit valuable pharmacological activity and are useful especially as selective α2-receptor antagonists. Processes for the preparation of these compounds and pharmaceutical compositions containing them are described.

  式中的化合物： 其中 X 是-CH2-、- -或-0-，R1 是 H、低级烷基或低级烯基、O 或 O ，R2 是 H、CH3、 、O 或 OH，R3 是 H、 、 、O 或 Hal，R4 是 H、 、 、O 或 Hal，Hal 是卤素，它们的无毒酸加成盐具有宝贵的药理活性，尤其可用作选择性 α2-受体拮抗剂。本文介绍了制备这些化合物和含有它们的药物组合物的工艺。
• US4689339A
  申请人：——

  公开号：US4689339A

  公开（公告）日：1987-08-25
• US7592461B2
  申请人：——

  公开号：US7592461B2

  公开（公告）日：2009-09-22